Neurology
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
QUICK SEARCH:   [advanced]


     

This Article
Right arrow Figures Only
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Data Supplement
Right arrow Correspondence:
Submit a response
Right arrow Alert me when this article is cited
Right arrow Alert me when Correspondence are posted
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow reprints & permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Tintner, R.
Right arrow Articles by Jankovic, J.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Tintner, R.
Right arrow Articles by Jankovic, J.
NEUROLOGY 2005;65:765-767
© 2005 American Academy of Neurology
Brief Communications

Autonomic function after botulinum toxin type A or B: A double-blind, randomized trial

R. Tintner, MD, R. Gross, MD, U. F. Winzer, MD, K. A. Smalky, MD and J. Jankovic, MD

Departments of Neurology (Drs. Tintner, Winzer, and Jankovic), Ophthalmology (Dr. Gross), and Internal Medicine (Dr. Smalky), Baylor College of Medicine, Houston, TX.

Address correspondence and reprint requests to Dr. Ron Tintner, The Methodist Hospital, 6560 Fannin St., Suite 902, Houston, TX 77030; e-mail: rtintner{at}tmh.tmc.edu

To compare autonomic effects of botulinum toxin (BTX), we randomized patients with cervical dystonia to receive either BTX-A or BTX-B in a double-blind manner. Efficacy and physiologic questionnaire measures of autonomic function were assessed at baseline and 2 weeks after injection. Patients treated with BTX-B had less saliva production (p < 0.01) and greater severity of constipation (p = 0.037) than those treated with BTX-A, but did not differ in other tests of autonomic functions.

Additional material related to this article can be found on the Neurology Web site. Go to www.neurology.org and scroll down the Table of Contents for the September 13 issue to find the link for this article.

Supported by a grant from Allergan, Irvine, CA, which manufactures the Botox formulation of BTX-A.

Received September 22, 2004. Accepted in final form April 11, 2004.

Disclosure: The authors report no conflicts of interest.




This article has been cited by other articles:


Home page
 Clin Med ResHome page
S. Ozcakir and K. Sivrioglu
Botulinum Toxin in Poststroke Spasticity
Clin. Med. Res., June 1, 2007; 5(2): 132 - 138.
[Abstract] [Full Text] [PDF]

Home page
 J Child NeurolHome page
T. D. Sanger, S. N. Kukke, and S. Sherman-Levine
Botulinum Toxin Type B Improves the Speed of Reaching in Children With Cerebral Palsy and Arm Dystonia: An Open-Label, Dose-Escalation Pilot Study
J Child Neurol, January 1, 2007; 22(1): 116 - 122.
[Abstract] [PDF]

Home page
 NeurologyHome page
J. Jankovic, C. Hunter, B. Z. Dolimbek, G. S. Dolimbek, C. H. Adler, A. Brashear, C. L. Comella, M. Gordon, D. E. Riley, K. Sethi, et al.
Clinico-immunologic aspects of botulinum toxin type B treatment of cervical dystonia
Neurology, December 26, 2006; 67(12): 2233 - 2235.
[Abstract] [Full Text] [PDF]


HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Copyright © 2005 by AAN Enterprises, Inc.